The development of PARP inhibitors in ovarian cancer: from bench to bedside
The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.
Br J Cancer 2015; 113 Suppl 1: S3-9. doi:10.1038/bjc.2015.394
Keywords: olaparib; PARP; ovarian cancer